Larimar Therapeutics, Inc. LRMR 深 沪
已收盘 11-13 16:00:00 美东时间
3.02
+0.320
+11.85%
华盛通- 最 高3.075
- 今 开3.01
- 成交量 253.15万股
- 最 低 2.835
- 昨 收 2.70
- 总市值 3.14亿
- 52周最高 6.42
- 市盈率 静 --
- 换手率 2.44%
- 52周最低 1.915
- 委 比 -64.79%
- 总股本 1.04亿
- 历史最高 664.32
- 量 比 2.65
- 振 幅 8.89%
- 历史最低 1.53
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Larimar Therapeutics announced that its management team will participate in a fireside chat and investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston from November 9-11, 2026. The fireside chat will take place on November 10, 2026, at 10:00 AM EST, with a webcast available. A replay will be accessible for 30 days on the company’s website. Larimar, a biotech company focused on treatments for rare diseases, is de...
11-04 21:05
Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon...
09-30 04:06
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Larimar Therapeutics appoints John Harlow as President and Chief Operating Officer. With over 25 years of experience in the biopharmaceutical industry, Harlow will lead commercial and operational efforts to advance nomlabofusp, a potential treatment for Friedreich’s ataxia. His appointment aims to support the company’s growth and global launch of its lead compound.
09-29 20:05
Century Therapeutics Appoints Joseph Truitt to Board of Directors
Century Therapeutics appoints Joseph Truitt to its Board of Directors. Truitt, CEO of iECURE and Chairman of Larimar Therapeutics, brings extensive leadership experience in biotech. Century is advancing CNTY-813, an iPSC-derived therapy for type 1 diabetes, toward IND submission, and CNTY-308, a CAR-iT cell therapy for B-cell diseases, toward clinical entry, both leveraging its Allo-Evasion™ platform.
09-09 20:05
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play
Larimar Therapeutics, Inc. ($LRMR) announced an update on their ongoing clinica...
09-04 00:32
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
08-05 21:24
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share from the same period last year.
08-04 19:12
美股牛股 | 生物制药公司FBRX大涨逾78%！关键药物研究成果积极；地热电力公司FRVO股价劲升16%
生物制药公司FBRX大涨逾78%！关键药物研究成果积极；地热电力公司FRVO股价劲升16%，地热开发项目取得重要进展；贵金属概念股TXG涨15%！此前获大摩大幅上调目标价>>
07-10 19:22
Larimar Therapeutics shares are trading higher after a Form 4 filing indicated that a Director bought 50K shares at an average price of $3.34 per share.
Larimar Therapeutics shares are trading higher after a Form 4 filing indicated that a Director bought 50K shares at an average price of $3.34 per share.
07-10 02:20
